On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu published a patent.Computed Properties of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders. And the patent contained the following:
The invention relates to coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof as novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2, R3, R4, X, and Y are as defined in the disclosure, are claimed. Example compounds such as II were prepared by multistep synthesis and evaluated in vitro and in vivo for their activity as CFTR correctors (data shown). Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis and chronic obstructive pulmonary diseases). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Computed Properties of 25813-24-5
The Article related to coumarin preparation cftr corrector chronic obstructive pulmonary disease treatment, Heterocyclic Compounds (One Hetero Atom): Benzopyrans (Including Coumarins, Isocoumarins, Chromones, Benzopyrones, Dibenzopyrans, and Other Arenopyrans) and other aspects.Computed Properties of 25813-24-5